Forsythe, Elizabeth

Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period

Haqq, A. M., Chung, W. K., Dollfus, H., Haws, R. M., Martos-Moreno, G. Á., Poitou, C., Yanovski, J. A., Mittleman, R. S., Yuan, G., Forsythe, E., et al. (2022) · The Lancet Diabetes & Endocrinology

Genetic and Kidney Cyst DiseasesPharmacology and Obesity Treatment

Cited by 206

Bardet–Biedl Syndrome ciliopathy is linked to altered hematopoiesis and dysregulated self-tolerance

Tsyklauri, O., Niederlova, V., Forsythe, E., Prasai, A., Drobek, A., Kasparek, P., Sparks, K., Trachtulec, Z., Prochazka, J., Sedlacek, R., et al. (2021) · The EMBO Reports

Genetic and Kidney Cyst DiseasesCystic Fibrosis Research Advances

Cited by 39